v3.26.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Apr. 30, 2026
Oct. 31, 2025
Current assets:    
Cash and cash equivalents $ 1,477 $ 1,244
Short-term investments 12,209 13,930
Receivables 56
Prepaid expenses and other current assets 950 713
Total current assets 14,692 15,887
Operating lease right-of-use asset 173 193
Total assets 14,865 16,080
Current liabilities:    
Accounts payable 252 165
Accrued expenses 1,205 1,761
Operating lease liability 44 41
Total current liabilities 1,501 1,967
Operating lease liability, non-current 140 163
Total liabilities 1,641 2,130
Commitments and contingencies (Note 10)  
Shareholders’ equity:    
Preferred stock, value
Common stock, par value $.01 per share; 100,000,000 shares authorized; 33,922,776 and 33,013,829 shares issued and outstanding as of April 30, 2026 and October 31, 2025, respectively 339 330
Additional paid-in capital 270,894 266,508
Accumulated deficit (256,758) (251,677)
Total shareholders’ equity 14,475 15,161
Noncontrolling interest (Note 2) (1,251) (1,211)
Total equity 13,224 13,950
Total liabilities and equity 14,865 16,080
Series A Convertible Preferred Stock [Member]    
Shareholders’ equity:    
Preferred stock, value

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL
v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Apr. 30, 2026
Apr. 30, 2025
Apr. 30, 2026
Apr. 30, 2025
Income Statement [Abstract]        
Revenue
Operating expenses:        
Research and development expenses (including non-cash stock-based compensation expenses of $286, $417, $624 and $814, respectively) 1,258 1,322 2,360 2,874
General and administrative expenses (including non-cash stock-based compensation expenses of $379, $571, $837 and $1,229, respectively) 1,389 1,681 3,003 3,515
Total operating expenses 2,647 3,003 5,363 6,389
Loss from operations (2,647) (3,003) (5,363) (6,389)
Interest income 111 190 242 363
Net loss (2,536) (2,813) (5,121) (6,026)
Less: Net loss attributable to noncontrolling interest (20) (23) (40) (52)
Net loss attributable to common shareholders $ (2,516) $ (2,790) $ (5,081) $ (5,974)
Net loss per common share attributable to common shareholders:        
Basic $ (0.07) $ (0.09) $ (0.15) $ (0.19)
Diluted $ (0.07) $ (0.09) $ (0.15) $ (0.19)
Weighted average common shares outstanding:        
Basic 33,593 32,202 33,413 32,200
Diluted 33,593 32,202 33,413 32,200

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL
v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Apr. 30, 2026
Apr. 30, 2025
Reconciliation of net loss to net cash used in operating activities:    
Net loss $ (5,121) $ (6,026)
Stock option compensation to employees and directors 1,405 1,993
Stock options issued to consultants 56 50
Amortization of operating lease right-of-use asset 20 18
Amortization of discount on held-to-maturity securities 71 (79)
Change in operating assets and liabilities:    
Receivables (56) 173
Prepaid expenses and other current assets (237) 96
Accounts payable 87 (241)
Accrued expenses (556) (380)
Operating lease liability (20) (11)
Net cash used in operating activities (4,351) (4,407)
Cash flows from investing activities:    
Disbursements to acquire short-term investments (24,642) (24,929)
Proceeds from maturities of short-term investments 26,292 29,974
Net cash provided by investing activities 1,650 5,045
Cash flows from financing activities:    
Proceeds (expenses) from sale of common stock in an at-the-market offering, net of offering expenses of $135 and $51, respectively 2,870 (3)
Proceeds from sale of common stock pursuant to an employee stock purchase plan 4 4
Proceeds from exercise of stock options 60
Net cash provided by financing activities 2,934 1
Net increase in cash and cash equivalents 233 639
Cash and cash equivalents at beginning of period 1,244 1,271
Cash and cash equivalents at end of period $ 1,477 $ 1,910

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL